 OncLive | Novartis showcases ongoing research at ASCO to help patients fight various ... MarketWatch (press release) An 18-month analysis from the Phase III BOLERO-2 study (Breast cancer trials of OraL EveROlimus) (abstract #559; June 2, 8:00AM - 12:00PM) confirm that Afinitor® (everolimus) plus exemestane, an aromatase inhibitor, more than doubled the time ... Novartis Showcases Ongoing Research At ASCO To Fight Various Cancers |
